Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Working To Resolve GMP Issues That Derailed Sarilumab Approval

Executive Summary

CEO Olivier Brandicourt says Sanofi's Le Train, France, fill-and-finish facility should be back in FDA’s good graces before the PDUFA goal date for another Sanofi antibody, dupilumab.

Advertisement

Related Content

CDER Safety Outcomes Trials Group Vetted Kevzara CV Study Need
Kevzara: Sanofi Caught In Middle Of US FDA Debate On Data Analysis
Keeping Track: Immunology In Focus As US FDA Approves Kevzara, New Breakthrough Actemra Use; J&J, Sun Advance Psoriasis Candidates
Keeping Track: US FDA Shoots Down Lilly's Baricitinib, Approves Neurocrine's Ingrezza
Longtime Genzyme Holdout Meeker Passes Reigns To Sibold
Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
"Transformative" Dupilumab Set For Third Quarter Filing In Atopic Dermatitis

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119424

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel